Retinal and Choroidal Microvascular Assessment of Children Receiving Recombinant Growth Hormone Therapy.

Retinal and Choroidal Microvascular Assessment of Children Receiving Recombinant Growth Hormone Therapy. - Retinal and Choroidal Microvascular Assessment of Children Receiving Recombinant Growth Hormone Therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055654

Enrollment

Registered

2024-10-01

Start date

2024-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

observational study

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Enrollment of the patients in the study was based on age equal to or less than 16 years old, and patients were not receiving any therapy other than recombinant GH for group 1, clear ocular media, and no history of chronic ocular or systemic diseases.

Exclusion criteria

Exclusion criteria: The patients were excluded from the study if they had a history of preterm or small-for-gestational-age birth, a diagnosis of cardiovascular disease, thyroid disease, hepatic or renal disorder, obesity, current hypertension, or the presence of chromosomal abnormalities. Also, the study did not include children with high myopia, hyperopia, amblyopia, or ocular disease

Design outcomes

Primary

Measure	Time frame
Compared to healthy individuals, children receiving recombinant growth hormone therapy showed no changes in the retinal and choroidal microvasculature or macular thickness	—

Countries

Africa

Contacts

Public ContactIsmail Omar

Minia university hospital Ophthalmology

ismail.omar@mu.edu.eg+201002554116

Outcome results